Lenalidomid bazlı tedavi alan multiple myelom hastalarında gelişen advers olayların retrospektif değerlendirilmesi
Küçük Resim Yok
Tarih
2025
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Düzce Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Çalışmanın amacı, lenalidomid bazlı tedavi almakta olan Multiple Myelom hastalarında gelişen ve lenalidomid ile ilişkilendirilmiş yan etkileri detaylı bir şekilde incelemektir. Bu retrospektif çalışma, 1 Ocak 2014-31 Aralık 2024 tarihleri arasında hastanemiz hematoloji polikliniğinde takip edilmiş olan ve lenalidomid bazlı tedavi rejimleri almış olan MM hastaları üzerinde gerçekleştirilmiştir. Çalışmaya toplam 75 hasta dahil edilmiştir. Hastaların yaş, cinsiyet, performans durumu, miyelom tipi, hastalık evresi, kemik tutulumu ve plazmositom varlığı, başvuru anındaki laboratuvar verileri, hastaların aldığı tedaviler, OKİT (otolog kök hücre nakli) yapılıp yapılmadığı, yapılamayan hastalarda yapılamama nedenleri, lenalidomid idame ve maruziyet süreleri, lenalidomid tedavisine bağlı gelişen yan etkiler, tedavi sırasında doz azaltma gerekip gerekmediği, doz azaltma nedenleri, lenalidomid tedavisinin kesilmesi gerektiği durumlarda kesilme nedenleri değerlendirilmiştir. Çalışma kapsamında lenalidomid + deksametazon (LenDex), bortezomib + lenalidomid + deksametazon (VRd), karfilzomib + lenalidomid + deksametazon (KRd), daratumumab + lenalidomid + deksametazon (DRd), iksazomib + lenalidomid + deksametazon (İxaLenDex), lenalidomid + siklofosfamid + deksametazon (RCD) ve idame lenalidomid tedavileri sırasında gelişen ve litaratürde lenalidomid ile ilişkilendirilmiş hematolojik, gastrointestinal, dermatolojik, nörolojik, tromboembolik ve sekonder malignite olan yan etkilerin gelişimi değerlendirilmiştir. Çalışmamız sonucunda hastaların epidemiyolojik ve demografik verileri, lenalidomid ilişkili yan etkilerin gelişme sıklığı literatürle uyumlu saptanmıştır. Lenalidomid içeren farklı tedavi rejimlerinde gelişen yan etkiler birbirleriyle kıyaslanmış olup gelişen enfeksiyonlar dışında rejimler arası anlamlı bir fark saptanmadı. Söz konusu yan etkilerin lenalidomid dozunun düşürülmesine veya tedavinin kesilmesine yol açabileceği saptandı.
The aim of this study is to comprehensively investigate the adverse effects associated with lenalidomide in patients with multiple myeloma (MM) receiving lenalidomide-based treatment regimens. This retrospective study was conducted on MM patients who were treated in the hematology outpatient clinic of our hospital between January 1, 2014, and December 31, 2024, and who received lenalidomide-based therapies. A total of 75 patients were included in the study. Collected data included patients' age, sex, performance status, type of myeloma, disease stage, presence of bone involvement and plasmacytoma, laboratory parameters at diagnosis, treatment regimens received, whether autologous stem cell transplantation (ASCT) was performed, reasons for not undergoing ASCT in non-eligible patients, duration of lenalidomide maintenance and total exposure, adverse effects associated with lenalidomide therapy, need for dose modification during treatment, reasons for dose modification or treatment termination evaluated. Within the scope of the study, adverse effects that developed during treatment with lenalidomide + dexamethasone (LenDex), bortezomib + lenalidomide + dexamethasone (VRd), carfilzomib + lenalidomide + dexamethasone (KRd), daratumumab + lenalidomide + dexamethasone (DRd), ixazomib + lenalidomide + dexamethasone (IxaLenDex), lenalidomide + cyclophosphamide + dexamethasone (RCD), and lenalidomide maintenance were evaluated. Specifically, hematological, gastrointestinal, dermatological, neurological, thromboembolic adverse effects and secondary malignancies previously reported in the literature to be associated with lenalidomide were assessed. The epidemiological and demographic characteristics of the patients, as well as the incidence of lenalidomide associated adverse events, were found to be consistent with data reported in the literature. No statistically significant differences were observed in the adverse event profiles, except enfections among different lenalidomide based treatment regimens. However, the observed adverse effects were determined to potentially necessitate dose reductions or termination of lenalidomide therapy.
The aim of this study is to comprehensively investigate the adverse effects associated with lenalidomide in patients with multiple myeloma (MM) receiving lenalidomide-based treatment regimens. This retrospective study was conducted on MM patients who were treated in the hematology outpatient clinic of our hospital between January 1, 2014, and December 31, 2024, and who received lenalidomide-based therapies. A total of 75 patients were included in the study. Collected data included patients' age, sex, performance status, type of myeloma, disease stage, presence of bone involvement and plasmacytoma, laboratory parameters at diagnosis, treatment regimens received, whether autologous stem cell transplantation (ASCT) was performed, reasons for not undergoing ASCT in non-eligible patients, duration of lenalidomide maintenance and total exposure, adverse effects associated with lenalidomide therapy, need for dose modification during treatment, reasons for dose modification or treatment termination evaluated. Within the scope of the study, adverse effects that developed during treatment with lenalidomide + dexamethasone (LenDex), bortezomib + lenalidomide + dexamethasone (VRd), carfilzomib + lenalidomide + dexamethasone (KRd), daratumumab + lenalidomide + dexamethasone (DRd), ixazomib + lenalidomide + dexamethasone (IxaLenDex), lenalidomide + cyclophosphamide + dexamethasone (RCD), and lenalidomide maintenance were evaluated. Specifically, hematological, gastrointestinal, dermatological, neurological, thromboembolic adverse effects and secondary malignancies previously reported in the literature to be associated with lenalidomide were assessed. The epidemiological and demographic characteristics of the patients, as well as the incidence of lenalidomide associated adverse events, were found to be consistent with data reported in the literature. No statistically significant differences were observed in the adverse event profiles, except enfections among different lenalidomide based treatment regimens. However, the observed adverse effects were determined to potentially necessitate dose reductions or termination of lenalidomide therapy.
Açıklama
Anahtar Kelimeler
Hematoloji, Hematology
